linjc16/ctgov huggingface dataset:
Operative Versus Non Operative Treatment of Proximal Humerus (Shoulder Joint) Fractures

Study Overview
=================
Brief Summary
-----------------
To determine if operative treatment of non operative management of these fractures is best. Hypothesis: There is no difference in functional outcome between operative and non-operatively treated 3- and 4-part proximal humerus fractures at one year's time.

Detailed Description
-----------------
Participants of 70 years of age or older who have been medically assessed as 'fit for surgery' are randomly (like flipping a coin) to either operative or non operative management of their injury. Clinical follow-up including x-rays, and physical assessment of injured shoulder, and outcomes questionnaires will be used to determine which if either resulted in the best outcome.

Official Title
-----------------
A Multicentre Prospective Randomized Control Trial on the Treatment of Three and Four Part Proximal Humerus Fractures in Patients 70 Years and Older: Comparing Open Reduction and Internal Fixation With Non Operative Treatment

Conditions
-----------------
3 and 4 Part Proximal Humerus Fractures

Intervention / Treatment
-----------------
* Other: Open reduction internal fixation; reduction and immobilization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Proximal humerus fracture patients

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Operative<br>Treatment arm - intervention = Open Reduction Internal Fixation or Reduction & Immobilization | Other: Open reduction internal fixation; reduction and immobilization<br> <br> |
| No Intervention: Non Operative<br>Placebo arm | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary outcome measurement will be the patients' functional shoulder scores as measured by the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional and mental status instruments (i.e. SF-36/EQ-5D) used to assess the patient's health-related quality of life;, re-operation rates; and the time required to return to pre-injury level of independence |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Operative, Non operative
Effects Whole Body Vibration in Ergospirometrics Parameters and Quality of Life

Study Overview
=================
Brief Summary
-----------------
This study makes sure that the training of whole body vibration induces changes in ergospirometric parameters, in strength and influence in quality of life in healthy elderly. A case that is run like a vibration training combined, increasing strength and VO2.

Detailed Description
-----------------
The search use the spirometric values after whole body vibration training and resistance training

Official Title
-----------------
Effects Whole Body Vibration in Ergospirometrics Parameters, Strength And Quality of Life: A Randomised Controlled Trial

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Procedure: WHOLE BODY VIBRATION


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 60 to 74 years sedentary or irregularly active according to the IPAQ short form with no known diseases Exclusion Criteria: smoking acute hernia thrombosis labyrinthitis diabetes hemodynamic instability obesity osteoporosis neuromuscular diseases pulmonary comorbidities heart disease electrocardiographic changes during exercise taking medications that affected bone metabolism or muscle and don't adapt to any of the protocols

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: WHOLE BODY VIBRATION<br>SEARCH THE CARDIOPULMONARY EFFECTS IN WHOLE BODY VIBRATION IN HEALTH ELDERLY | Procedure: WHOLE BODY VIBRATION<br>* 03 MONTHS, TWICE PER WEEK<br>* Other names: POWER PLATE, MODEL MY3;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VO2 | change to maximal oxygen consumption (ml.kg.min)in ergospirometric test after 03 months training in vibrating platform twice per weeck. | 03 MONTHS IN INTERVENTION | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life | outcome measure with the SF 36 shot form (Medical Outcomes Study 36 - Item short form health survey)after 03 months training in vibrating platform twice per weeck | 03 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
WHOLE BODY VIBRATION, AGED, VO2, muscle strength
Impact of Neurally Adjusted Ventilator Assist (NAVA) Mode on Patient Ventilator Asynchrony Using Helmet

Study Overview
=================
Brief Summary
-----------------
Non invasive ventilation has been proposed to reduce the incidence of ventilatory dysfunction following abdominal aortic surgery. However, the nasogastric tube reduces the airtightness of the facial mask used to perform non invasive ventilation and induces air leaks. The use of a helmet reduces air leaks, thus seems adequate to ensure patient-ventilator interface. However, the high dead space related to helmet volume is responsible for asynchrony between patient demand and ventilatory support delivery. The investigators hypothesized driving the ventilator based on a neural signal (diaphragm electrical activity) would reduce patient-ventilator asynchronies.

Official Title
-----------------
Study of the Benefit of the NAVA Mode Versus PSV Mode on Patient Ventilator Asynchrony During Non Invasive Ventilation With Helmet

Conditions
-----------------
Non-Invasive Positive-Pressure Ventilation

Intervention / Treatment
-----------------
* Device: Neurally Adjusted Ventilatory Assistance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with increased risk of postoperative ventilatory dysfunction following abdominal aortic surgery Exclusion Criteria: Contra-indication to non-invasive ventilation pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Neurally Adjusted Ventilatory Assistance|In ICU following abdominal aortic surgery, in extubated patient, non-invasive ventilation was performed as follows: facial mask with non-invasive pressure support ventilation mode to define settings for helmet ventilation helmet use with non-invasive pressure support ventilation mode to define adequate settings helmet use with neurally adjusted ventilatory assist mode, based on previous settings|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Triggering delay | Duration between the onset of neural inspiration and the onset of insufflation | Every inspiration, for 10 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cycling off delay | Delay between the end of neural inspiration and the end of insufflation | Every inspiration, for 10 minutes |
Registry of Acute Coronary Syndrome From University Hospital of Vigo

Study Overview
=================
Brief Summary
-----------------
CardoCHUVI registry was aim to study ischemic and bleeding complication after an acute coronary syndrome (ACS), both in-hospital and follow-up events.

Detailed Description
-----------------
CardioCHUVI is a retrospective study aim to analyze all consecutively patients admitted by acute coronary syndrome to University Hospital Alvaro Cunqueiro of Vigo, between January 2010 to January 2018 The objective of the project was to study cardiac and bleeding complications, such as reinfarction, heart failure, atrial fibrillation, stroke, and bleeding events, together with all-cause and cardiac mortality

Official Title
-----------------
Registry of Patients Admitted by Acute Coronary Syndrome to University Hospital of Vigo

Conditions
-----------------
Acute Coronary Syndrome

Intervention / Treatment
-----------------
* Drug: Dual antiplatelet therapy with ticagrelor/prasuglre


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient admitted to University Hospital Alvaro Cunqueiro of Vigo for acute coronary syndrome. Exclusion Criteria: Secondary acute coronary syndromes during a hospital admission for another cause (i.e. acute myocardial infarction in the context of a sepsis)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality | Death for any cause | Through study completion, an average of 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reinfarction | New spontaneous acute myocardial infarction | Through study completion, an average of 3 years | 
| Bleeding | Any bleeding according to BARC definition (from 1 to 5) | Through study completion, an average of 3 years | 
| Ischemic stroke | Ischemic stroke documented in CT | Through study completion, an average of 3 years | 
| Cancer | Any type of malignant cancer | Through study completion, an average of 3 years | 
| Heart Failure | Heart Failure admissions | Through study completion, an average of 3 years | 
| Atrial Fibrillation | Atrial fibrillation documented in ECG | Through study completion, an average of 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Coronary Syndrome; Bleeding; Dual antiplatelet therapy
A Phase I Study of iPS Cell Generation From Patients With COPD

Study Overview
=================
Brief Summary
-----------------
As part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and pulmonary hypertension, the investigators will assess the feasibility of collecting skin biopsies from patients undergoing surgery for thoracic disease, culturing skin fibroblasts from the biopsy, and reprogramming these skin fibroblasts into induced pluripotent cells.

Official Title
-----------------
A Phase I Study of iPS Cell Generation From Patients With COPD

Conditions
-----------------
Thoracic Diseases, Respiratory Tract Diseases, Cancer of Lung, Cancer of the Lung, Lung Cancer, Lung Diseases, Obstructive, COPD, Pulmonary Emphysema, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell

Intervention / Treatment
-----------------
* Other: Skin Biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing Thoracic Surgery at the Mayo Clinic Rochester Presence of a Thoracic Disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Skin Biopsy<br> | Other: Skin Biopsy<br>* Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility | As part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and pulmonary hypertension, we will assess the feasibility of collecting skin biopsies from patients undergoing surgery for thoracic disease, culturing skin fibroblasts from the biopsy, and reprogramming these skin fibroblasts into induced pluripotent cells. Markers of induced pluripotent phenotype will be utilized to assess successful reprogramming. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lung, cancer, thoracic, chest, pulmonary
Serum and Peritoneal Fluid Bank for Endometriosis Markers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate differences in protein expression profiles of blood and peritoneal fluid samples obtained from patients who do, and those who do not, have endometriosis seen during laparoscopic surgery. These profiles may include both known and novel markers for diagnosing endometriosis.

Official Title
-----------------
Serum and Peritoneal Fluid Bank for Assessment of Markers of Endometriosis

Conditions
-----------------
Endometriosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing laparoscopic surgery for one of the following indications: infertility pain tubal sterilization For cases, visualization of endometriosis For controls, absence of endometriosis Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometriosis
Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations

Study Overview
=================
Brief Summary
-----------------
The analysis of HIV resistance to antiretrovirals (Sanger sequencing on RNA) is difficult when the viral load is undetectable or during therapeutic breaks. In these situations, the ultra-deep sequencing (UDS) can be done on proviral DNA in order to improve characterization of archived resistant variants with may reflect past virological failures. This study is a cross-sectional study which will require only one additional tube which can be taken during a routine check-up as part of the usual follow-up of the individuals included.

Official Title
-----------------
Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations

Conditions
-----------------
HIV-1-infection

Intervention / Treatment
-----------------
* Biological: Blood samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who has given consent Adult patient Patient living with HIV-1 Controlled viral load (<50 RNA copies/ml) for at least 1 year. At least two previous virologic failures, either : Initial failure : defined as the persistence of a viral load greater than 50 copies/ml beyond 1 year, after the initiation of triple antiretroviral therapy, and without virological control (VL > 50 copies/ml) since the initiation of the very first antiretroviral treatment. A rebound in HIV viral load to more than 50 copies/ml after a period of virological success, confirmed on two consecutive samples at least one month apart. At least 2 Sanger RNA genotypes have been done or could be done from the existing library. Exclusion Criteria: Patient not affiliated to a medical insurance scheme Protected adult Pregnant, parturient or breastfeeding woman Discontinuation of clinical and immuno-virological follow-up for more than 2 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Blood samples|An additional blood tube will be taken during the patient's follow-up blood collection.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| > Genotyping Score (GSS) comparison between HIV DNA-UDS genotyping assay obtained at inclusion and cumulative RNA-Sanger genotyping assays obtained at each virological failure during routine follow |  | baseline |
Virtual Physical Activity for Type 1 Diabetes

Study Overview
=================
Brief Summary
-----------------
A virtual group of teens with type 1 diabetes, led by young adults with type 1 diabetes, will play active videogames and discuss activity and health. This study will evaluate the program for feasibility and user satisfaction.

Official Title
-----------------
A Virtual Home Intervention to Promote Physical Activity Among Youth With Type 1 Diabetes

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Behavioral: Virtual home intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of 14-19 years Diagnosis of type 1 diabetes or other absolute insulin deficiency diabetes for ≥6 months Inadequate moderate-to-vigorous physical activity levels (defined as ≤3 days per week achieving ≥60min daily, which is ≤50% of the recommended 7 days per week) English literacy Own a continuous glucose monitor (Dexcom G4, G5, G6 [San Diego, CA], Abbott Freestyle Libre 2, 14-day [Chicago, IL], Medtronic Guardian 3, Enlite [Dublin, Ireland]) with enough supplies for 6 weeks (when available, we will provide these to those who do not own them, in which case they will be considered to meet this criteria). Access to television or computer with HDMI or USB port. Under regular care by a healthcare provider (defined as attending at least one appointment in the past year, plus access to verified 24hr phone number to reach the provider's team for insulin dose adjustments if assistance is needed) Exclusion Criteria: • A condition or disability besides type 1 diabetes that would preclude participation in group moderate-to-vigorous physical activity (e.g., cerebral palsy, current pregnancy)

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br>Virtual home intervention | Behavioral: Virtual home intervention<br>* Group classes with active videogames and discussions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence | Number of group classes attended | 6 weeks | 
| Acceptability | Score on a satisfaction survey that has been custom-designed for the components of this program. Scores range from 0 to 4. A higher score indicates greater satisfaction with the program. | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise, Adolescent, Video games, Self-management, Social support